ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "James Williams, MS, DO, FACEP - NOAC Update"
Episode Synopsis
The popularity of NOACs has grown. Numerically, though they are safe, it’s likely that the Emergency Physician will see more and more bleeds, especially in a trauma situation. In early May, Portola Pharmaceuticals got FDA approval for the targeted reversal agent, Andexanet, as indicated for the reversal of Eliquis and Xarelto. Dr. Williams breaks down the research on this episode of ACEP’s Frontline.
Support for this segment was provided in-part by Portola Pharmaceuticals.
Support for this segment was provided in-part by Portola Pharmaceuticals.
More episodes of the podcast ACEP Frontline - Emergency Medicine
Frontline Headliners with Dr. Amal Mattu
08/10/2025
Frontline Headliners with Dr. Mel Herbert
23/09/2025
In God we trust